These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15904536)

  • 41. Update on the cost-effectiveness of screening for colorectal neoplasia.
    Inadomi JM
    Curr Opin Gastroenterol; 2003 Jan; 19(1):44-50. PubMed ID: 15699893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening for colorectal cancer using the faecal occult blood test, hemoccult.
    Towler BP; Irwig L; Glasziou P; Weller D; Kewenter J
    Cochrane Database Syst Rev; 2000; (2):CD001216. PubMed ID: 10796760
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer.
    Redaelli A; Cranor CW; Okano GJ; Reese PR
    Pharmacoeconomics; 2003; 21(17):1213-38. PubMed ID: 14986736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
    Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
    JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost benefit of early diagnosis of colorectal cancer.
    Bolin TD
    Scand J Gastroenterol Suppl; 1996; 220():142-6. PubMed ID: 8898453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Colon Cancer Screening - Is It Time Yet?
    Bhurgri H; Samiullah S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.
    Ladabaum U; Chopra CL; Huang G; Scheiman JM; Chernew ME; Fendrick AM
    Ann Intern Med; 2001 Nov; 135(9):769-81. PubMed ID: 11694102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Visual screening for malignant melanoma: a cost-effectiveness analysis.
    Losina E; Walensky RP; Geller A; Beddingfield FC; Wolf LL; Gilchrest BA; Freedberg KA
    Arch Dermatol; 2007 Jan; 143(1):21-8. PubMed ID: 17224538
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Markov's modeling for screening strategies for colorectal cancer.
    Barouni M; Larizadeh MH; Sabermahani A; Ghaderi H
    Asian Pac J Cancer Prev; 2012; 13(10):5125-9. PubMed ID: 23244122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recommendations on population screening for colorectal cancer in New Zealand. Members of the National Health Committee Working Party on Population Screening for Colorectal Cancer.
    N Z Med J; 1999 Jan; 112(1080):4-6. PubMed ID: 10073156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
    Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative effectiveness of screening strategies for colorectal cancer.
    Barzi A; Lenz HJ; Quinn DI; Sadeghi S
    Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
    Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
    Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
    Ladabaum U; Allen J; Wandell M; Ramsey S
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.